19:15 , Jul 19, 2019 |  BC Extra  |  Financial News

July 19 Financial Quick Takes: Amarin raises cash ahead of Vascepa PDUFA date, plus Atara, Sunstone and Forendo

Ahead of Vascepa push, Amarin adds $400M to coffers  With the Sept. 28 PDUFA date looming for a potential expansion of the label for Vascepa icosapent to include reduced cardiovascular risk, Amarin Corp. plc (NASDAQ:AMRN)...
21:21 , Jun 14, 2019 |  BioCentury  |  Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
18:35 , Jun 7, 2019 |  BC Extra  |  Clinical News

June 7 Clinical Quick Takes: Takeda discontinues Ninlaro for amyloidosis; plus La Jolla, Innovent and Atara

Takeda discontinues amyloidosis trial  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) discontinued the Phase III TOURMALINE-AL1 trial to treat relapsed or refractory systemic amyloid light-chain (AL) amyloidosis after Ninlaro ixazomib plus dexamethasone missed the first of...
10:52 , Jun 7, 2019 |  BC Extra  |  Company News

As Sanofi enters growth phase, Novartis exec Hudson to take the helm

Novartis has lost one executive from each of its Innovative Medicines units in the span of three days, now that Sanofi has named seasoned British sales and marketing executive Paul Hudson as the successor to...
22:01 , May 30, 2019 |  BC Extra  |  Company News

Management tracks: Sanofi hires Atara's Berger; plus Emmaus, enGene and more

Two days after Atara Biotherapeutics Inc. (NASDAQ:ATRA) announced Dietmar Berger was departing as global head of R&D, Sanofi (Euronext:SAN; NASDAQ:SNY) has announced he will oversee its clinical portfolio as head of development. Prior to his...
22:43 , May 28, 2019 |  BC Extra  |  Company News

Management tracks: Atara names Novartis’ Touchon as CEO; plus Intellia, Arch Oncology

Atara Biotherapeutics Inc. (NASDAQ:ATRA) hired Pascal Touchon as president and CEO, effective June 24. He was global head cell & gene at Novartis AG (NYSE:NVS; SIX:NOVN), where he was responsible for the global launch of...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
14:35 , Apr 1, 2019 |  BC Extra  |  Clinical News

MSKCC CAR T shows 72% response in mesothelioma

Researchers from MSKCC presented data for a mesothelin-targeted autologous CAR T cell therapy that could be the first to crack the solid tumor juggernaut for this treatment modality while also minimizing toxicity. The data could...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
23:50 , Jan 3, 2019 |  BC Extra  |  Company News

Management tracks: Barrett joins UroGen

Uro-oncology company UroGen Pharma Ltd. (NASDAQ:URGN) named Elizabeth Barrett as president and CEO. She replaces Ron Bentsur. Last month, Barrett joined the exodus of pharma leaders heading to biotech as she departed Novartis AG (NYSE:NVS;...